MedJobScout :: Health :: Medicine :: Medical Specialties :: Internal Medicine :: Publications

All Internal Medicine Jobs

Permanent Internal Medicine Job in Lexington Kentucky with Eagle Hospital Physicians
As one of Eagle Hospital Physicians first practices (starting in 1999), this group practice covers two different hospital locations and three facilities-- Saint Joseph and Saint Joseph East and the Continuing
Permanent Internal Medicine Job in Valdosta Georgia with Eagle Hospital Physicians
Designated as south Georgia's newest metropolitan area and recognized as the business, cultural, educational, medical, leisure and retail hub of south Georgia and north Florida, Valdosta, Georgia is
Permanent Internal Medicine Job in Atlanta Georgia with Eagle Hospital Physicians
South Fulton Medical Center is a 338 bed acute care medical center conveniently located near Hartsfield Jackson International Airport with easy access to Atlantas major interstates, I-85, I-75 and I-285.

Current Opinion in Internal Medicine - Current Table Of Contents

Breastfeeding and allergies: time for a change in paradigm?.
Page: 539DOI: 10.1097/MCI.0b013e32831dae43Authors: Duncan, Joanne M; Sears, Malcolm R
New aspects in allergic contact dermatitis.
Page: 547DOI: 10.1097/MCI.0b013e32831dae50Authors: Mortz, Charlotte Gotthard; Andersen, Klaus Ejner
Contemporary approaches to the identification of athletes at risk for sudden cardiac death.
Page: 552DOI: 10.1097/MCI.0b013e32831daee4Authors: Drezner, Jonathan A

PubMed: 0003-4819

Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis.
Enomoto M, Nakamishi T, Ishii M, Tamori A, Kawada N Related Articles Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med. 2008 Dec 16;149(12):912-3 Authors: Enomoto M, Nakamishi T, Ishii M, Tamori A, Kawada N PMID: 19075218 [PubMed - indexed for MEDLINE]
Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir.
Kawakami T, Ooka S, Mizoguchi M, Soma Y, Yamazaki M Related Articles Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir. Ann Intern Med. 2008 Dec 16;149(12):911-2 Authors: Kawakami T, Ooka S, Mizoguchi M, Soma Y, Yamazaki M PMID: 19075217 [PubMed - indexed for MEDLINE]
Evaluating open access: problems with the program or the studies?
Salisbury C Related Articles Evaluating open access: problems with the program or the studies? Ann Intern Med. 2008 Dec 16;149(12):910; author reply 911 Authors: Salisbury C PMID: 19075216 [PubMed - indexed for MEDLINE]
Evaluating open access: problems with the program or the studies?
Kellermann AL Related Articles Evaluating open access: problems with the program or the studies? Ann Intern Med. 2008 Dec 16;149(12):910-1; author reply 911 Authors: Kellermann AL PMID: 19075215 [PubMed - indexed for MEDLINE]
Evaluating open access: problems with the program or the studies?
Murray MF Related Articles Evaluating open access: problems with the program or the studies? Ann Intern Med. 2008 Dec 16;149(12):909; author reply 911 Authors: Murray MF PMID: 19075214 [PubMed - indexed for MEDLINE]
Evaluating open access: problems with the program or the studies?
Anderson DR Related Articles Evaluating open access: problems with the program or the studies? Ann Intern Med. 2008 Dec 16;149(12):909-10; author reply 911 Authors: Anderson DR PMID: 19075213 [PubMed - indexed for MEDLINE]

Archives of Internal Medicine current issue

ANNUAL REVIEWERS LIST: Reviewers Who Completed a Review During 2008
Mon, 08 Dec 2008 00:00:00 -0000

ABOUT THIS JOURNAL: About This Journal
Mon, 08 Dec 2008 00:00:00 -0000

IN THIS ISSUE OF ARCHIVES OF INTERNAL MEDICINE: In This Issue of Archives of Internal Medicine
Mon, 08 Dec 2008 00:00:00 -0000

EDITORIAL: Changing of the Guard: New Editor for Archives of Internal Medicine
Greenland, P. Mon, 08 Dec 2008 00:00:00 -0000

EDITORIAL: Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?
Falsey, A. R. Mon, 08 Dec 2008 00:00:00 -0000

INVITED COMMENTARY: Integrated Monitoring Systems and Patient Safety: A Need for Further Study--Invited Commentary
Bellam, S. Mon, 08 Dec 2008 00:00:00 -0000

ORIGINAL INVESTIGATION: Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects on Immune Responses
Engler, R. J. M., Nelson, M. R., Klote, M. M., VanRaden, M. J., Huang, C.-Y., Cox, N. J., Klimov, A., Keitel, W. A., Nichol, K. L., Carr, W. W., Treanor, J. J., for the Walter Reed Health Care System Influenza Vaccine Consortium Mon, 08 Dec 2008 00:00:00 -0000
Background  Optimal public health strategies for managing influenza vaccine shortages are not yet defined. Our objective was to determine the effects of age, sex, and dose on the immunogenicity of intramuscular trivalent inactivated vaccine (TIV). Methods  Healthy adults aged 18 to 64 years, stratified by age (18-49 and 50-64 years) and sex, were randomized to receive full- or half-dose TIV. Hemagglutination inhibition titers against vaccine antigens were measured before and 21 days after immunization. A primary outcome of noninferiority was defined as a difference of less than 20% in the upper 95% confidence interval (CI) of the proportion of subjects with strain-specific hemagglutination inhibition antibody titers of 1:40 or higher after vaccination. Secondary outcomes included geometric mean titers, after vaccination side effects, and occurrences of influenza-like illnesses. Results  Among previously immunized subjects (N = 1114) receiving half- vs full-dose TIV (age, 18-49 years, n = 284 [half] and n = 274 [full]; and age 50-64 years, n = 276 [half] and n = 280 [full]), CIs for proportions of subjects with hemagglutination inhibition antibody titers of 1:40 or higher excluded substantial reduction for all antigens in the 18- to 49-year age group and for B/Shanghai/361/2002 (B) and A/Fujian/411/2002 (A/H3N2) in the 50- to 64-year age group. Geometric mean titer in the female 18- to 49-year age group exceeded male responses for all strains: responses to half-dose TIV that were comparable with male full-dose responses for A/New Caledonia/20/99 (A/H1N1) antigen, 25.4 (95% CI, 20.9-30.9) vs 25.6 (95% CI, 21.3-30.9); A/H3N2 antigen, 60.8 (95% CI, 50.8-72.7) vs 44.1 (95% CI, 37.6-51.8); and B antigen, 64.4 (95% CI, 53.9-76.9) vs 60.7 (95% CI, 51.4-71.7) (findings were similar for the 50- to 64-year age group). Some injection site and systemic reactions (myalgias and/or arthralgias [P < .05], headache [P < .001], and impact of fatigue [P < .05]) were significantly lower in men. The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose groups regardless of age. Conclusions  Antibody responses to intramuscular half-dose TIV in healthy, previously immunized adults were not substantially inferior to the full-dose vaccine, particularly for ages 18 to 49 years. Significantly higher geometric mean titer responses in women were identified for all ages, regardless of dose or influenza strain. Half-dose vaccination may be an effective strategy for healthy adults younger than 50 years in the setting of an influenza vaccine shortage. Trial Registration  clinicaltrials.gov Identifier: NCT00283283
ORIGINAL INVESTIGATION: Comparative Effectiveness of Different {beta}-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice
Go, A. S., Yang, J., Gurwitz, J. H., Hsu, J., Lane, K., Platt, R. Mon, 08 Dec 2008 00:00:00 -0000
Background  Randomized trials have demonstrated the efficacy of selected β-blockers in systolic heart failure, but the comparative effectiveness of different β-blockers in practice is poorly understood. Methods  We compared mortality associated with different β-blockers following hospitalization for heart failure between 2001 and 2003. Longitudinal exposure to β-blockers was ascertained from pharmacy databases. Patient characteristics and other medication use were identified from administrative, hospitalization, outpatient, and pharmacy databases. Death was identified from administrative, state mortality, and Social Security Administration databases. Multivariate Cox regression was used to examine the association between different β-blockers and death. Results  Among 11 326 adults surviving a hospitalization for heart failure, 7976 received β-blockers (atenolol, 38.5%; metoprolol tartrate, 43.2%; carvedilol, 11.6%; and other, 6.7%) during follow-up. The rate (per 100 person-years) of death during the 12 months after discharge varied by exposure and type of β-blocker (atenolol, 20.1; metoprolol tartrate, 22.8; carvedilol, 17.7; and no β-blockers, 37.0). After adjustment for confounders and the propensity to receive carvedilol, the risk of death compared with atenolol was higher for metoprolol tartrate (adjusted hazard ratio [HR], 1.16; 95% confidence interval [CI], 1.01-1.34) and no β-blockers (HR, 1.63; 95% CI, 1.44-1.84) but was not significantly different for carvedilol (HR, 1.16; 95% CI, 0.92-1.44). Conclusions  Compared with atenolol, the adjusted risks of death were slightly higher with shorter-acting metoprolol tartrate but did not significantly differ for carvedilol in adults with heart failure. Our results should be interpreted cautiously and they suggest the need for randomized trials within real-world settings comparing a broader spectrum of β-blockers for heart failure.
ORIGINAL INVESTIGATION: Comparative Effectiveness of {beta}-Blockers in Elderly Patients With Heart Failure
Kramer, J. M., Curtis, L. H., Dupree, C. S., Pelter, D., Hernandez, A., Massing, M., Anstrom, K. J. Mon, 08 Dec 2008 00:00:00 -0000
Background  Whether β-blockers (BBs) other than carvedilol, metoprolol succinate, and bisoprolol fumarate (evidence-based β-blockers [EBBBs]) improve survival in patients with heart failure (HF) is unknown. We compared the effectiveness of EBBBs vs non-EBBBs on survival. Methods  Our study population included North Carolina residents at least 65 years old who were eligible for Medicare and Medicaid with pharmacy benefits and had had at least 1 hospitalization for HF during the period 2001 through 2004. Primary outcome was survival from 30 days to 1 year. Secondary outcomes included number and days of rehospitalizations for HF and number of outpatient visits. Cohorts were defined by BB class (EBBBs, non-EBBBs, or no BBs) in first 30 days after discharge from index hospitalization for HF. Outcomes were analyzed using inverse probability–weighted (IPW) estimators with propensity score adjustment. Results  Of 11 959 patients, 40% were nonwhite, 79% were female, and 26% were at least 85 years old. Fifty-nine percent received no BB, 23% received EBBBs, and 18% received non-EBBBs. One-year adjusted mortality rates were 28.3% (no BBs), 22.8% (non-EBBBs), and 24.2% (EBBBs). The IPW-adjusted comparisons of 1-year mortality outcomes for either non-EBBBs or EBBBs compared with no BBs were statistically significant (P = .002 for both), but there was no statistical difference between the 2 BB groups (P = .43). The IPW-adjusted mean numbers of rehospitalizations for HF were 0.33 (no BBs), 0.29 (non-EBBBs), and 0.41 (EBBBs), with statistically more rehospitalizations in patients receiving EBBBs compared with no BBs (P = .002) and with non-EBBBs (P < .001). Conclusion  In this elderly population, the comparative effectiveness of EBBBs vs non-EBBBs was similar for 1-year survival, whereas the rehospitalization rate was higher for patients receiving EBBBs.

Current Opinion in Internal Medicine - Current Table Of Contents

Breastfeeding and allergies: time for a change in paradigm?.
Page: 539DOI: 10.1097/MCI.0b013e32831dae43Authors: Duncan, Joanne M; Sears, Malcolm R
New aspects in allergic contact dermatitis.
Page: 547DOI: 10.1097/MCI.0b013e32831dae50Authors: Mortz, Charlotte Gotthard; Andersen, Klaus Ejner
Contemporary approaches to the identification of athletes at risk for sudden cardiac death.
Page: 552DOI: 10.1097/MCI.0b013e32831daee4Authors: Drezner, Jonathan A
How to break the vicious circle of antibiotic resistances?.
Page: 560DOI: 10.1097/MCI.0b013e32831dabd1Authors: Leone, Marc; Martin, Claude
Benefits of high-protein weight loss diets: enough evidence for practice?.
Page: 566DOI: 10.1097/MCI.0b013e32831daebdAuthors: Brehm, Bonnie J a; D'Alessio, David A b
Chronic pancreatitis.
Page: 572DOI: 10.1097/MCI.0b013e32831daddaAuthors: Conwell, Darwin L; Banks, Peter A

Subscribe to Publications RSS feed